Salvato in:
Dettagli Bibliografici
Autori principali: Hallie Coltin, Ofélie Trudeau‐Ferrin, Sébastien Perreault, Lucie Lafay‐Cousin, Derek S. Tsang, Samuele Renzi, Valérie Larouche, Craig Erker, Juliette Hukin, Randy Barber, Paul C. Nathan, Annie Huang, Eric Bouffet, Vijay Ramaswamy
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:https://onlinelibrary.wiley.com/doi/10.1002/pbc.32024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867018233627803648
author Hallie Coltin
Ofélie Trudeau‐Ferrin
Sébastien Perreault
Lucie Lafay‐Cousin
Derek S. Tsang
Samuele Renzi
Valérie Larouche
Craig Erker
Juliette Hukin
Randy Barber
Paul C. Nathan
Annie Huang
Eric Bouffet
Vijay Ramaswamy
author_facet Hallie Coltin
Ofélie Trudeau‐Ferrin
Sébastien Perreault
Lucie Lafay‐Cousin
Derek S. Tsang
Samuele Renzi
Valérie Larouche
Craig Erker
Juliette Hukin
Randy Barber
Paul C. Nathan
Annie Huang
Eric Bouffet
Vijay Ramaswamy
Hallie Coltin
Ofélie Trudeau‐Ferrin
Sébastien Perreault
Lucie Lafay‐Cousin
Derek S. Tsang
Samuele Renzi
Valérie Larouche
Craig Erker
Juliette Hukin
Randy Barber
Paul C. Nathan
Annie Huang
Eric Bouffet
Vijay Ramaswamy
collection Wiley Open Access
contents Severe Hearing Loss in Children With Central Nervous System Tumors: A Population‐Based Cancer in Young People in Canada (CYP‐C) Report Hallie Coltin Ofélie Trudeau‐Ferrin Sébastien Perreault Lucie Lafay‐Cousin Derek S. Tsang Samuele Renzi Valérie Larouche Craig Erker Juliette Hukin Randy Barber Paul C. Nathan Annie Huang Eric Bouffet Vijay Ramaswamy Pediatric Blood & Cancer ABSTRACTPurposeChildren with central nervous system (CNS) tumors are prone to treatment‐related hearing loss (HL) and subsequent functional impairment. This study reports a dedicated population‐based analysis of CNS tumor‐specific rates and predictors of early severe HL.MethodsA cohort study of children ≤15 years diagnosed with CNS tumors between 2001 and 2019 through the Cancer in Young People in Canada (CYP‐C) program. The primary outcome was Grade 3 and 4 severe HL within 5 years following diagnosis.ResultsAmong 3201 children with CNS tumors, 5.1% experienced early severe HL. Children with medulloblastoma (N = 570) and ATRT/other embryonal tumors (N = 269) had higher rates of early HL (16.1%, 15.2%, respectively). Cisplatin was administered to 80.1% of children with embryonal tumors, and 67.3% received radiotherapy. In children with medulloblastoma, age less than 6 years at diagnosis (OR 2.4, 1.5–3.8; vs. ≥6 years), radiation (OR 3.5, 1.6–7.6), and cisplatin (OR 20.4, 1.3–329.7) predicted early severe HL. Younger age at diagnosis doubled the probability of early severe HL (10.6% in <6 years vs. 4.8% in ≥6 years), while radiation exposure tripled the probability across age groups (29.8% and 10.6% if <6 years; 15.3% and 4.8% in ≥6 years). In children with ATRT/other embryonal tumors, cisplatin (OR 31.6, 1.9–521.9) was the sole predictor of early severe HL.ConclusionsHigh rates of early HL were observed in children with embryonal tumors. Younger children who received radiotherapy had higher probabilities of early HL, suggesting an additive interaction between age and radiation. Standardized otoprotection and research on cisplatin avoidance and therapy de‐escalation in young children with embryonal tumors are urgently needed. 10.1002/pbc.32024 http://creativecommons.org/licenses/by-nc/4.0/
doi_str_mv 10.1002/pbc.32024
format Artículo Open Access
id wiley_oa_10_1002_pbc_32024
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Severe Hearing Loss in Children With Central Nervous System Tumors: A Population‐Based Cancer in Young People in Canada (CYP‐C) Report
Hallie Coltin
Ofélie Trudeau‐Ferrin
Sébastien Perreault
Lucie Lafay‐Cousin
Derek S. Tsang
Samuele Renzi
Valérie Larouche
Craig Erker
Juliette Hukin
Randy Barber
Paul C. Nathan
Annie Huang
Eric Bouffet
Vijay Ramaswamy
Pediatric Blood & Cancer
Severe Hearing Loss in Children With Central Nervous System Tumors: A Population‐Based Cancer in Young People in Canada (CYP‐C) Report Hallie Coltin Ofélie Trudeau‐Ferrin Sébastien Perreault Lucie Lafay‐Cousin Derek S. Tsang Samuele Renzi Valérie Larouche Craig Erker Juliette Hukin Randy Barber Paul C. Nathan Annie Huang Eric Bouffet Vijay Ramaswamy Pediatric Blood & Cancer ABSTRACTPurposeChildren with central nervous system (CNS) tumors are prone to treatment‐related hearing loss (HL) and subsequent functional impairment. This study reports a dedicated population‐based analysis of CNS tumor‐specific rates and predictors of early severe HL.MethodsA cohort study of children ≤15 years diagnosed with CNS tumors between 2001 and 2019 through the Cancer in Young People in Canada (CYP‐C) program. The primary outcome was Grade 3 and 4 severe HL within 5 years following diagnosis.ResultsAmong 3201 children with CNS tumors, 5.1% experienced early severe HL. Children with medulloblastoma (N = 570) and ATRT/other embryonal tumors (N = 269) had higher rates of early HL (16.1%, 15.2%, respectively). Cisplatin was administered to 80.1% of children with embryonal tumors, and 67.3% received radiotherapy. In children with medulloblastoma, age less than 6 years at diagnosis (OR 2.4, 1.5–3.8; vs. ≥6 years), radiation (OR 3.5, 1.6–7.6), and cisplatin (OR 20.4, 1.3–329.7) predicted early severe HL. Younger age at diagnosis doubled the probability of early severe HL (10.6% in <6 years vs. 4.8% in ≥6 years), while radiation exposure tripled the probability across age groups (29.8% and 10.6% if <6 years; 15.3% and 4.8% in ≥6 years). In children with ATRT/other embryonal tumors, cisplatin (OR 31.6, 1.9–521.9) was the sole predictor of early severe HL.ConclusionsHigh rates of early HL were observed in children with embryonal tumors. Younger children who received radiotherapy had higher probabilities of early HL, suggesting an additive interaction between age and radiation. Standardized otoprotection and research on cisplatin avoidance and therapy de‐escalation in young children with embryonal tumors are urgently needed. 10.1002/pbc.32024 http://creativecommons.org/licenses/by-nc/4.0/
title Severe Hearing Loss in Children With Central Nervous System Tumors: A Population‐Based Cancer in Young People in Canada (CYP‐C) Report
topic Pediatric Blood & Cancer
url https://onlinelibrary.wiley.com/doi/10.1002/pbc.32024